Detail of "39284-23-6"

Reference

Neutron activation for iron-59-labeling of oral iron preparations for bioavailability measurements in man

Heinrich, H. C.; Fischer, R.; Gabbe, E. E. (Univ. Hosp. Eppendorf, Univ. Hamburg, Hamburg 2000, Fed. Rep. 39284-23-6 which is the cas registry number of some chemical is mentioned. Ger.). Spec. Publ. - R. Soc. Chem., 72(Nutr. Availability: Chem. Biol. Aspects), 209-12 (English) 1989. CODEN: SROCDO. ISSN: 0260-6291. DOCUMENT TYPE: Journal CA Section: 18 (Animal Nutrition) The reliable quant. and direct estn. of the bioavailability of Fe in com. oral Fe prepns. was conducted by 59Fe labeling of the prepns. by neutron activation and was calcd. from the whole body retention of absorbed 59Fe. The bioavailability of Fe from com. oral Fe(II) and Fe(III) prepns. was best detd. on an empty stomach as it can be severely inhibited by a great no. of natural Fe-chelating compds. found particularly in vegetable foods and drinks. Healthy male volunteers with normal Fe stores absorbed 7.70% (Eryfer) and 7.63% (Ascofer) from Fe(II) ascorbate-contg. gelatin capsules with quick and complete Fe(II) release in the stomach, whereas the 59Fe absorption was increased to 16.2% and 15.1%, resp., in Fe-depleted volunteers. From 59Fe(II) diaspartate (Spartocine)-contg. gelatin capsules 7.02% was absorbed with normal Fe stores and 14.0% with depleted Fe stores. The bioavailability of 59Fe from a 59Fe(II) gluconate plus citrate and tartarate in addn. to ascorbate-contg. sparkling tablet (Losferron) was reduced to 3.11% with normal Fe stores and 8.24% with depleted Fe stores. The bioavailability of 59Fe from an oral Fe(II) prepn. with delayed rapid Fe(II) release in the duodenum at pH 5.5-6.8 (ferro sanol duodenal) was slightly reduced to 6.55% in subjects with normal Fe stores and 14.5% with depleted Fe stores. The bioavailability from a sustained or controlled release tablet with a delayed but finally complete Fe release (Kendural C) and that from a mucoprotease-contg. 59Fe(II)SO4 dragee (Tardyferon) were reduced to 4.52% and 3.37% in subjects with normal Fe stores and 9.89% and 10.71% in those with depleted Fe stores, resp. The 59Fe bioavailability from a 59Fe(III)-citrate complex in soln. (Ferrlecit drops) was considerably reduced to 1.58% and 2.30% in subjects with normal and depleted Fe stores, resp. The lowest 59Fe bioavailability (0.81%) was obsd. in volunteers with normal Fe stores with a Fe(III)-hydroxide-polymaltose complex (Ferrum Hausmam drops and juice). An Fe chelate tablet reported to contain only Fe(II) chelated to soybean proteins and protein hydrolyzate showed 59Fe bioavailability of 4.01% and 10.1% in normal depleted Fe stores, resp. .